Théa
Théa, announces the development of a structured roadmap to reduce its greenhouse gas emissions, in alignment with international climate objectives and the global ambition of carbon neutrality by 2045.
2/18/26
Innovation
Tsubota Laboratory announces the achievement of First Patient In (FPI) in the global Phase 2 clinical trial of TLM-003, an investigational eye drop developed to suppress myopia progression, marking a key milestone in its international clinical dev...
2/11/26
Théa
Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline.
12/4/25
Théa
Sepul Bio: Théa’s Innovative Unit Doses First in Phase 3 HYPERION Trial for LCA10
10/1/25
Welcome to our testimonials section. Discover the inspiring stories of our employees, managers and healthcare professionals who share their experience with Laboratoires Théa.
General Direction
Read the interview with Jean-Frédéric Chibret, President of Théa
Joining Théa means opening your eyes to opportunities for professional development. Training, career development, international mobility... our skills development program supports you throughout your career.
Ready to join the Théa adventure? We're looking for profiles and personalities ready to innovate, whatever their field of expertise.
